Safe drugs with high potential to block malaria transmission revealed by a spleen-mimetic screening
Malaria parasites like Plasmodium falciparum multiply in red blood cells (RBC), which are cleared from the bloodstream by the spleen when their deformability is altered. Drug-induced stiffening of Plasmodium falciparum -infected RBC should therefore induce their elimination from the bloodstream. Her...
Saved in:
| Published in | Nature communications Vol. 14; no. 1; pp. 1951 - 16 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
London
Nature Publishing Group UK
07.04.2023
Nature Publishing Group Nature Portfolio |
| Subjects | |
| Online Access | Get full text |
| ISSN | 2041-1723 2041-1723 |
| DOI | 10.1038/s41467-023-37359-2 |
Cover
| Abstract | Malaria parasites like
Plasmodium falciparum
multiply in red blood cells (RBC), which are cleared from the bloodstream by the spleen when their deformability is altered. Drug-induced stiffening of
Plasmodium falciparum
-infected RBC should therefore induce their elimination from the bloodstream. Here, based on this original mechanical approach, we identify safe drugs with strong potential to block the malaria transmission. By screening 13 555 compounds with spleen-mimetic microfilters, we identified 82 that target circulating transmissible form of
P. falciparum
. NITD609, an orally administered PfATPase inhibitor with known effects on
P. falciparum
, killed and stiffened transmission stages in vitro at nanomolar concentrations. Short exposures to TD-6450, an orally-administered NS5A hepatitis C virus inhibitor, stiffened transmission parasite stages and killed asexual stages in vitro at high nanomolar concentrations. A Phase 1 study in humans with a primary safety outcome and a secondary pharmacokinetics outcome (
https://clinicaltrials.gov
, ID: NCT02022306) showed no severe adverse events either with single or multiple doses. Pharmacokinetic modelling showed that these concentrations can be reached in the plasma of subjects receiving short courses of TD-6450. This physiologically relevant screen identified multiple mechanisms of action, and safe drugs with strong potential as malaria transmission-blocking agents which could be rapidly tested in clinical trials.
Authors propose their splenic mimetic filtration method, microsphiltration, and utilise this approach in a drug-screen, to identify compounds that induce a stiffening effect on
Plasmodium falciparum
-infected erythrocytes. They proceed to assess safety and tolerability of one identified compound in a phase I clinical trial. |
|---|---|
| AbstractList | Malaria parasites like
Plasmodium falciparum
multiply in red blood cells (RBC), which are cleared from the bloodstream by the spleen when their deformability is altered. Drug-induced stiffening of
Plasmodium falciparum
-infected RBC should therefore induce their elimination from the bloodstream. Here, based on this original mechanical approach, we identify safe drugs with strong potential to block the malaria transmission. By screening 13 555 compounds with spleen-mimetic microfilters, we identified 82 that target circulating transmissible form of
P. falciparum
. NITD609, an orally administered PfATPase inhibitor with known effects on
P. falciparum
, killed and stiffened transmission stages in vitro at nanomolar concentrations. Short exposures to TD-6450, an orally-administered NS5A hepatitis C virus inhibitor, stiffened transmission parasite stages and killed asexual stages in vitro at high nanomolar concentrations. A Phase 1 study in humans with a primary safety outcome and a secondary pharmacokinetics outcome (
https://clinicaltrials.gov
, ID: NCT02022306) showed no severe adverse events either with single or multiple doses. Pharmacokinetic modelling showed that these concentrations can be reached in the plasma of subjects receiving short courses of TD-6450. This physiologically relevant screen identified multiple mechanisms of action, and safe drugs with strong potential as malaria transmission-blocking agents which could be rapidly tested in clinical trials.
Authors propose their splenic mimetic filtration method, microsphiltration, and utilise this approach in a drug-screen, to identify compounds that induce a stiffening effect on
Plasmodium falciparum
-infected erythrocytes. They proceed to assess safety and tolerability of one identified compound in a phase I clinical trial. Authors propose their splenic mimetic filtration method, microsphiltration, and utilise this approach in a drug-screen, to identify compounds that induce a stiffening effect on Plasmodium falciparum-infected erythrocytes. They proceed to assess safety and tolerability of one identified compound in a phase I clinical trial. Malaria parasites like Plasmodium falciparum multiply in red blood cells (RBC), which are cleared from the bloodstream by the spleen when their deformability is altered. Drug-induced stiffening of Plasmodium falciparum -infected RBC should therefore induce their elimination from the bloodstream. Here, based on this original mechanical approach, we identify safe drugs with strong potential to block the malaria transmission. By screening 13 555 compounds with spleen-mimetic microfilters, we identified 82 that target circulating transmissible form of P. falciparum . NITD609, an orally administered PfATPase inhibitor with known effects on P. falciparum , killed and stiffened transmission stages in vitro at nanomolar concentrations. Short exposures to TD-6450, an orally-administered NS5A hepatitis C virus inhibitor, stiffened transmission parasite stages and killed asexual stages in vitro at high nanomolar concentrations. A Phase 1 study in humans with a primary safety outcome and a secondary pharmacokinetics outcome ( https://clinicaltrials.gov , ID: NCT02022306) showed no severe adverse events either with single or multiple doses. Pharmacokinetic modelling showed that these concentrations can be reached in the plasma of subjects receiving short courses of TD-6450. This physiologically relevant screen identified multiple mechanisms of action, and safe drugs with strong potential as malaria transmission-blocking agents which could be rapidly tested in clinical trials. Malaria parasites like Plasmodium falciparum multiply in red blood cells (RBC), which are cleared from the bloodstream by the spleen when their deformability is altered. Drug-induced stiffening of Plasmodium falciparum-infected RBC should therefore induce their elimination from the bloodstream. Here, based on this original mechanical approach, we identify safe drugs with strong potential to block the malaria transmission. By screening 13 555 compounds with spleen-mimetic microfilters, we identified 82 that target circulating transmissible form of P. falciparum. NITD609, an orally administered PfATPase inhibitor with known effects on P. falciparum, killed and stiffened transmission stages in vitro at nanomolar concentrations. Short exposures to TD-6450, an orally-administered NS5A hepatitis C virus inhibitor, stiffened transmission parasite stages and killed asexual stages in vitro at high nanomolar concentrations. A Phase 1 study in humans with a primary safety outcome and a secondary pharmacokinetics outcome ( https://clinicaltrials.gov , ID: NCT02022306) showed no severe adverse events either with single or multiple doses. Pharmacokinetic modelling showed that these concentrations can be reached in the plasma of subjects receiving short courses of TD-6450. This physiologically relevant screen identified multiple mechanisms of action, and safe drugs with strong potential as malaria transmission-blocking agents which could be rapidly tested in clinical trials. Malaria parasites like Plasmodium falciparum multiply in red blood cells (RBC), which are cleared from the bloodstream by the spleen when their deformability is altered. Drug-induced stiffening of Plasmodium falciparum-infected RBC should therefore induce their elimination from the bloodstream. Here, based on this original mechanical approach, we identify safe drugs with strong potential to block the malaria transmission. By screening 13 555 compounds with spleen-mimetic microfilters, we identified 82 that target circulating transmissible form of P. falciparum. NITD609, an orally administered PfATPase inhibitor with known effects on P. falciparum, killed and stiffened transmission stages in vitro at nanomolar concentrations. Short exposures to TD-6450, an orally-administered NS5A hepatitis C virus inhibitor, stiffened transmission parasite stages and killed asexual stages in vitro at high nanomolar concentrations. A Phase 1 study in humans with a primary safety outcome and a secondary pharmacokinetics outcome (https://clinicaltrials.gov, ID: NCT02022306) showed no severe adverse events either with single or multiple doses. Pharmacokinetic modelling showed that these concentrations can be reached in the plasma of subjects receiving short courses of TD-6450. This physiologically relevant screen identified multiple mechanisms of action, and safe drugs with strong potential as malaria transmission-blocking agents which could be rapidly tested in clinical trials.Authors propose their splenic mimetic filtration method, microsphiltration, and utilise this approach in a drug-screen, to identify compounds that induce a stiffening effect on Plasmodium falciparum-infected erythrocytes. They proceed to assess safety and tolerability of one identified compound in a phase I clinical trial. Malaria parasites like Plasmodium falciparum multiply in red blood cells (RBC), which are cleared from the bloodstream by the spleen when their deformability is altered. Drug-induced stiffening of Plasmodium falciparum-infected RBC should therefore induce their elimination from the bloodstream. Here, based on this original mechanical approach, we identify safe drugs with strong potential to block the malaria transmission. By screening 13 555 compounds with spleen-mimetic microfilters, we identified 82 that target circulating transmissible form of P. falciparum. NITD609, an orally administered PfATPase inhibitor with known effects on P. falciparum, killed and stiffened transmission stages in vitro at nanomolar concentrations. Short exposures to TD-6450, an orally-administered NS5A hepatitis C virus inhibitor, stiffened transmission parasite stages and killed asexual stages in vitro at high nanomolar concentrations. A Phase 1 study in humans with a primary safety outcome and a secondary pharmacokinetics outcome ( https://clinicaltrials.gov , ID: NCT02022306) showed no severe adverse events either with single or multiple doses. Pharmacokinetic modelling showed that these concentrations can be reached in the plasma of subjects receiving short courses of TD-6450. This physiologically relevant screen identified multiple mechanisms of action, and safe drugs with strong potential as malaria transmission-blocking agents which could be rapidly tested in clinical trials.Malaria parasites like Plasmodium falciparum multiply in red blood cells (RBC), which are cleared from the bloodstream by the spleen when their deformability is altered. Drug-induced stiffening of Plasmodium falciparum-infected RBC should therefore induce their elimination from the bloodstream. Here, based on this original mechanical approach, we identify safe drugs with strong potential to block the malaria transmission. By screening 13 555 compounds with spleen-mimetic microfilters, we identified 82 that target circulating transmissible form of P. falciparum. NITD609, an orally administered PfATPase inhibitor with known effects on P. falciparum, killed and stiffened transmission stages in vitro at nanomolar concentrations. Short exposures to TD-6450, an orally-administered NS5A hepatitis C virus inhibitor, stiffened transmission parasite stages and killed asexual stages in vitro at high nanomolar concentrations. A Phase 1 study in humans with a primary safety outcome and a secondary pharmacokinetics outcome ( https://clinicaltrials.gov , ID: NCT02022306) showed no severe adverse events either with single or multiple doses. Pharmacokinetic modelling showed that these concentrations can be reached in the plasma of subjects receiving short courses of TD-6450. This physiologically relevant screen identified multiple mechanisms of action, and safe drugs with strong potential as malaria transmission-blocking agents which could be rapidly tested in clinical trials. |
| ArticleNumber | 1951 |
| Author | Roussel, Camille Amireault, Pascal Gamo, Francisco Javier Sanz, Laura Maria Beher, Babette Buffet, Pierre García-Barbazán, Irene Sissoko, Abdoulaye Carucci, Mario Gamallo, Pablo Ndour, Papa Alioune Dao, Ming Fricot-Monsinjon, Aurélie Dumas, Lucie Duez, Julien McNamara, Case W. Dussiot, Michael Tarning, Joel Hull, Mitchell V. |
| Author_xml | – sequence: 1 givenname: Mario orcidid: 0000-0002-1559-4302 surname: Carucci fullname: Carucci, Mario organization: Université Paris Cité, Inserm, UMR-1134, Biologie Intégré du Globule Rouge – sequence: 2 givenname: Julien orcidid: 0000-0002-5416-5084 surname: Duez fullname: Duez, Julien organization: SYNSIGHT – sequence: 3 givenname: Joel orcidid: 0000-0003-4566-4030 surname: Tarning fullname: Tarning, Joel organization: Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford – sequence: 4 givenname: Irene orcidid: 0000-0003-4372-9646 surname: García-Barbazán fullname: García-Barbazán, Irene organization: Mycology Reference Laboratory, National Centre for Microbiology, Instituto de Salud Carlos III – sequence: 5 givenname: Aurélie surname: Fricot-Monsinjon fullname: Fricot-Monsinjon, Aurélie organization: Université Paris Cité, Inserm, UMR-1134, Biologie Intégré du Globule Rouge – sequence: 6 givenname: Abdoulaye orcidid: 0000-0002-9986-0494 surname: Sissoko fullname: Sissoko, Abdoulaye organization: Université Paris Cité, Inserm, UMR-1134, Biologie Intégré du Globule Rouge – sequence: 7 givenname: Lucie surname: Dumas fullname: Dumas, Lucie organization: Université Paris Cité, Inserm, UMR-1134, Biologie Intégré du Globule Rouge – sequence: 8 givenname: Pablo orcidid: 0000-0002-2429-0984 surname: Gamallo fullname: Gamallo, Pablo organization: Global Health Medicines R&D, GlaxoSmith Kline (GSK) – sequence: 9 givenname: Babette surname: Beher fullname: Beher, Babette organization: Université Paris Cité, Inserm, UMR-1134, Biologie Intégré du Globule Rouge – sequence: 10 givenname: Pascal orcidid: 0000-0002-5562-7586 surname: Amireault fullname: Amireault, Pascal organization: Université Paris Cité, Inserm, UMR-1134, Biologie Intégré du Globule Rouge, Laboratory of cellular and molecular mechanisms of hematological disorders and therapeutic implications, INSERM – sequence: 11 givenname: Michael surname: Dussiot fullname: Dussiot, Michael organization: Laboratory of cellular and molecular mechanisms of hematological disorders and therapeutic implications, INSERM, Laboratoire d’Excellence GR-Ex – sequence: 12 givenname: Ming orcidid: 0000-0001-5372-385X surname: Dao fullname: Dao, Ming organization: Department of Materials Science and Engineering, Massachusetts Institute of Technology – sequence: 13 givenname: Mitchell V. surname: Hull fullname: Hull, Mitchell V. organization: Calibr, a division of The Scripps Research Institute – sequence: 14 givenname: Case W. surname: McNamara fullname: McNamara, Case W. organization: Calibr, a division of The Scripps Research Institute – sequence: 15 givenname: Camille surname: Roussel fullname: Roussel, Camille organization: Université Paris Cité, Inserm, UMR-1134, Biologie Intégré du Globule Rouge, Laboratoire d’Excellence GR-Ex, Laboratoire d’Hématologie générale, Hôpital Universitaire Necker Enfants Malades, Assistance Publique–Hôpitaux de Paris (AP-HP) – sequence: 16 givenname: Papa Alioune orcidid: 0000-0001-7203-9754 surname: Ndour fullname: Ndour, Papa Alioune organization: Université Paris Cité, Inserm, UMR-1134, Biologie Intégré du Globule Rouge – sequence: 17 givenname: Laura Maria orcidid: 0000-0003-0796-5211 surname: Sanz fullname: Sanz, Laura Maria organization: Global Health Medicines R&D, GlaxoSmith Kline (GSK) – sequence: 18 givenname: Francisco Javier orcidid: 0000-0002-1854-2882 surname: Gamo fullname: Gamo, Francisco Javier organization: Global Health Medicines R&D, GlaxoSmith Kline (GSK) – sequence: 19 givenname: Pierre surname: Buffet fullname: Buffet, Pierre email: pierre.buffet@inserm.fr organization: Université Paris Cité, Inserm, UMR-1134, Biologie Intégré du Globule Rouge, Department of Infectious & Tropical Disease, AP-HP, Necker Hospital, Centre Médical de l’Institut Pasteur (CMIP), Institut Pasteur |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/37029122$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kktv1TAQhSNURB_0D7BAltiwCdhj5-EVQhWUSpVYAGvLcSa5vjj2xU5a9d_j27TQdlEv_Dzn09F4josDHzwWxRtGPzDK249JMFE3JQVe8oZXsoQXxRFQwUrWAD94sD8sTlPa0jy4ZK0Qr4pD3lCQDOCoMD_0gKSPy5jItZ03ZGPHDdmFGf1stSNzIJ0L5jeZtNPRajJH7dNkU7LBk4hXqB32pLshmqSdQ_TlZCecrSHJxHy0fnxdvBy0S3h6t54Uv75--Xn2rbz8fn5x9vmyNJVgcwmUQoNQ97WpGdcd1FALqg10yLWsGoqmGrpKYkW5wQplTwWylg7IqxryfFJcrNw-6K3aRTvpeKOCtur2IsRR6ZiTOVQMatn2wrSyb8VgmBwyrgVEY7pqYDyzPq2s3dJN2JtcjqjdI-jjF283agxXilHaArA6E97fEWL4s2CaVa6aQee0x7AkBY1sG1aBlFn67ol0G5boc632qkbUkop9pLcPI_3Lcv-ZWdCuAhNDShEHZeys5_xROaF1OZrat45aW0fl1lG3raP2Vnhivac_a-KrKWWxHzH-j_2M6y-x69aR |
| CitedBy_id | crossref_primary_10_1097_MOH_0000000000000839 crossref_primary_10_3390_ph18030424 crossref_primary_10_1002_ajh_27481 crossref_primary_10_3390_molecules28217433 crossref_primary_10_1016_j_parint_2025_103041 |
| Cites_doi | 10.1016/j.chom.2015.12.001 10.1186/1475-2875-13-143 10.2307/3280287 10.1073/pnas.1810137115 10.1002/14651858.CD000363.pub2 10.1182/blood-2016-01-690776 10.1093/cid/ciaa368 10.1038/nprot.2016.056 10.1038/s42003-022-03510-w 10.1016/j.molbiopara.2021.111392 10.1038/nature14451 10.1128/AAC.06377-11 10.1016/j.nmd.2016.07.002 10.1007/s40268-017-0222-8 10.1007/978-1-62703-026-7_20 10.1371/journal.pone.0005318 10.1128/AAC.00325-13 10.1158/1535-7163.MCT-05-0442 10.1016/S2666-5247(20)30062-8 10.1182/blood-2012-01-404103 10.1371/journal.ppat.1006336 10.1182/blood-2012-03-414557 10.1056/NEJMe2110659 10.1128/AAC.04684-14 10.1126/science.6362007 10.1172/JCI106629 10.1038/nprot.2018.035 10.1002/jcph.789 10.3201/eid2110.150682 10.1182/blood-2010-10-312801 10.1016/S2666-5247(21)00356-6 10.1126/science.781840 10.1128/AAC.01940-16 10.1182/blood.V68.2.450.450 10.1038/ncomms6521 10.1128/AAC.02084-16 10.1111/mmi.13626 10.1038/s41467-018-05777-2 10.1056/NEJMoa1513137 10.1093/infdis/jiv358 10.1038/s41598-017-16671-0 10.3389/fphys.2019.01613 10.1056/NEJMoa2101746 10.1126/science.1193225 10.1093/infdis/jiz680 10.1056/NEJMc0900231 10.1182/blood-2005-10-4094 10.1182/blood-2008-03-146779 10.1056/NEJMoa1314981 10.1172/JCI156588 10.1111/j.1462-5822.2012.01786.x 10.1186/1472-6882-13-48 10.1007/s00894-018-3761-1 10.1128/AAC.02838-15 10.1177/108705719900400206 10.1371/journal.pone.0135139 10.1128/AAC.01053-18 10.1038/srep16414 10.1186/1475-2875-12-408 10.1186/s12936-016-1675-x 10.1093/jac/dkt165 10.1038/s41467-022-30133-w 10.1016/j.clinthera.2020.01.013 10.1182/blood.2020008563 10.1128/AAC.05030-14 10.1038/s41598-018-26819-1 10.1186/s12936-020-03421-3 |
| ContentType | Journal Article |
| Copyright | The Author(s) 2023 2023. The Author(s). The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| Copyright_xml | – notice: The Author(s) 2023 – notice: 2023. The Author(s). – notice: The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| DBID | C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7QL 7QP 7QR 7SN 7SS 7ST 7T5 7T7 7TM 7TO 7X7 7XB 88E 8AO 8FD 8FE 8FG 8FH 8FI 8FJ 8FK ABUWG AEUYN AFKRA ARAPS AZQEC BBNVY BENPR BGLVJ BHPHI C1K CCPQU DWQXO FR3 FYUFA GHDGH GNUQQ H94 HCIFZ K9. LK8 M0S M1P M7P P5Z P62 P64 PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS RC3 SOI 7X8 5PM DOA |
| DOI | 10.1038/s41467-023-37359-2 |
| DatabaseName | Springer Nature OA Free Journals CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Bacteriology Abstracts (Microbiology B) Calcium & Calcified Tissue Abstracts Chemoreception Abstracts Ecology Abstracts Entomology Abstracts (Full archive) Environment Abstracts Immunology Abstracts Industrial and Applied Microbiology Abstracts (Microbiology A) Nucleic Acids Abstracts Oncogenes and Growth Factors Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection Technology Research Database ProQuest SciTech Collection ProQuest Technology Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest One Sustainability ProQuest Central UK/Ireland Advanced Technologies & Aerospace Collection ProQuest Central Essentials Biological Science Collection ProQuest Central Technology Collection Natural Science Collection Environmental Sciences and Pollution Management ProQuest One Community College ProQuest Central Engineering Research Database Proquest Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student AIDS and Cancer Research Abstracts SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) Biological Sciences ProQuest Health & Medical Collection Medical Database Biological Science Database Advanced Technologies & Aerospace Database ProQuest Advanced Technologies & Aerospace Collection Biotechnology and BioEngineering Abstracts ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China Genetics Abstracts Environment Abstracts MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest Central Student Oncogenes and Growth Factors Abstracts ProQuest Advanced Technologies & Aerospace Collection ProQuest Central Essentials Nucleic Acids Abstracts SciTech Premium Collection ProQuest Central China Environmental Sciences and Pollution Management ProQuest One Applied & Life Sciences ProQuest One Sustainability Health Research Premium Collection Natural Science Collection Health & Medical Research Collection Biological Science Collection Chemoreception Abstracts Industrial and Applied Microbiology Abstracts (Microbiology A) ProQuest Central (New) ProQuest Medical Library (Alumni) Advanced Technologies & Aerospace Collection ProQuest Biological Science Collection ProQuest One Academic Eastern Edition ProQuest Hospital Collection ProQuest Technology Collection Health Research Premium Collection (Alumni) Biological Science Database Ecology Abstracts ProQuest Hospital Collection (Alumni) Biotechnology and BioEngineering Abstracts Entomology Abstracts ProQuest Health & Medical Complete ProQuest One Academic UKI Edition Engineering Research Database ProQuest One Academic Calcium & Calcified Tissue Abstracts ProQuest One Academic (New) Technology Collection Technology Research Database ProQuest One Academic Middle East (New) ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Central ProQuest Health & Medical Research Collection Genetics Abstracts Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Bacteriology Abstracts (Microbiology B) AIDS and Cancer Research Abstracts ProQuest SciTech Collection Advanced Technologies & Aerospace Database ProQuest Medical Library Immunology Abstracts Environment Abstracts ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | CrossRef MEDLINE Publicly Available Content Database MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: C6C name: Springer Nature OA Free Journals url: http://www.springeropen.com/ sourceTypes: Publisher – sequence: 2 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 3 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 4 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 5 dbid: 8FG name: ProQuest Technology Collection url: https://search.proquest.com/technologycollection1 sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Biology |
| EISSN | 2041-1723 |
| EndPage | 16 |
| ExternalDocumentID | oai_doaj_org_article_12698d4c89d84fc19fe9d82eeccb5f13 PMC10082216 37029122 10_1038_s41467_023_37359_2 |
| Genre | Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Extramural |
| GrantInformation_xml | – fundername: Bill and Melinda Gates Foundation (Bill & Melinda Gates Foundation) grantid: OPP1123683 funderid: https://doi.org/10.13039/100000865 – fundername: U.S. Department of Health & Human Services | National Institutes of Health (NIH) grantid: R01HL154150 funderid: https://doi.org/10.13039/100000002 – fundername: NHLBI NIH HHS grantid: R01 HL154150 – fundername: ; grantid: R01HL154150 – fundername: ; grantid: OPP1123683 |
| GroupedDBID | --- 0R~ 39C 3V. 53G 5VS 70F 7X7 88E 8AO 8FE 8FG 8FH 8FI 8FJ AAHBH AAJSJ ABUWG ACGFO ACGFS ACIWK ACMJI ACPRK ACSMW ADBBV ADFRT ADMLS ADRAZ AENEX AEUYN AFKRA AFRAH AHMBA AJTQC ALIPV ALMA_UNASSIGNED_HOLDINGS AMTXH AOIJS ARAPS ASPBG AVWKF AZFZN BBNVY BCNDV BENPR BGLVJ BHPHI BPHCQ BVXVI C6C CCPQU DIK EBLON EBS EE. EMOBN F5P FEDTE FYUFA GROUPED_DOAJ HCIFZ HMCUK HVGLF HYE HZ~ KQ8 LK8 M1P M48 M7P M~E NAO O9- OK1 P2P P62 PIMPY PQQKQ PROAC PSQYO RNS RNT RNTTT RPM SNYQT SV3 TSG UKHRP AASML AAYXX CITATION PHGZM PHGZT CGR CUY CVF ECM EIF NPM 7QL 7QP 7QR 7SN 7SS 7ST 7T5 7T7 7TM 7TO 7XB 8FD 8FK AARCD AZQEC C1K DWQXO FR3 GNUQQ H94 K9. P64 PJZUB PKEHL PPXIY PQEST PQGLB PQUKI PRINS RC3 SOI 7X8 PUEGO 5PM |
| ID | FETCH-LOGICAL-c541t-20027e26d6c613ab262640ac2be3a9570ec5fb59e503ce5e9d04e180fe3562fe3 |
| IEDL.DBID | M48 |
| ISSN | 2041-1723 |
| IngestDate | Wed Aug 27 01:30:39 EDT 2025 Thu Aug 21 18:38:16 EDT 2025 Fri Sep 05 06:04:52 EDT 2025 Wed Aug 13 04:55:11 EDT 2025 Wed Feb 19 02:24:35 EST 2025 Tue Jul 01 00:58:47 EDT 2025 Thu Apr 24 23:10:58 EDT 2025 Fri Feb 21 02:40:02 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Language | English |
| License | 2023. The Author(s). Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c541t-20027e26d6c613ab262640ac2be3a9570ec5fb59e503ce5e9d04e180fe3562fe3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| ORCID | 0000-0003-4566-4030 0000-0002-5562-7586 0000-0003-4372-9646 0000-0002-1559-4302 0000-0002-5416-5084 0000-0002-1854-2882 0000-0002-9986-0494 0000-0003-0796-5211 0000-0002-2429-0984 0000-0001-5372-385X 0000-0001-7203-9754 |
| OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.1038/s41467-023-37359-2 |
| PMID | 37029122 |
| PQID | 2797469043 |
| PQPubID | 546298 |
| PageCount | 16 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_12698d4c89d84fc19fe9d82eeccb5f13 pubmedcentral_primary_oai_pubmedcentral_nih_gov_10082216 proquest_miscellaneous_2798715299 proquest_journals_2797469043 pubmed_primary_37029122 crossref_citationtrail_10_1038_s41467_023_37359_2 crossref_primary_10_1038_s41467_023_37359_2 springer_journals_10_1038_s41467_023_37359_2 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2023-04-07 |
| PublicationDateYYYYMMDD | 2023-04-07 |
| PublicationDate_xml | – month: 04 year: 2023 text: 2023-04-07 day: 07 |
| PublicationDecade | 2020 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London – name: England |
| PublicationTitle | Nature communications |
| PublicationTitleAbbrev | Nat Commun |
| PublicationTitleAlternate | Nat Commun |
| PublicationYear | 2023 |
| Publisher | Nature Publishing Group UK Nature Publishing Group Nature Portfolio |
| Publisher_xml | – name: Nature Publishing Group UK – name: Nature Publishing Group – name: Nature Portfolio |
| References | MohandasNRossiMEClarkMRAssociation between morphologic distortion of sickle cells and deoxygenation-induced cation permeability increaseBlood1986684504541:CAS:528:DyaL28XkvFGnurw%3D373060910.1182/blood.V68.2.450.450 JagannathanPKakuruAMalaria in 2022: increasing challenges, cautious optimismNat. Commun.2022132022NatCo..13.2678J1:CAS:528:DC%2BB38Xht12mu7jP35562368910672710.1038/s41467-022-30133-w Lengeler, C. Insecticide‐treated bed nets and curtains for preventing malaria. Cochrane Database Syst. Rev. https://doi.org/10.1002/14651858.CD000363.pub2 (2004). Stone, W. et al. Single low-dose tafenoquine combined with dihydroartemisinin–piperaquine to reduce Plasmodium falciparum transmission in Ouelessebougou, Mali: a phase 2, single-blind, randomised clinical trial. Lancet Microbe3, e336–e347 (2022). Mogalian, E. et al. Preclinical Pharmacokinetics and first-in-human Pharmacokinetics, safety, and tolerability of Velpatasvir, a Pangenotypic Hepatitis C virus NS5A inhibitor, in healthy subjects. Antimicrob. Agents Chemother. 61, e02084-16 (2017). HienTTEstimation of the in vivo MIC of Cipargamin in uncomplicated Plasmodium falciparum MalariaAntimicrob. Agents Chemother.201761e01940161:CAS:528:DC%2BC2sXpsF2lsb8%3D27872070527873010.1128/AAC.01940-16 DuezJSplenic retention of Plasmodium falciparum gametocytes to block the transmission of MalariaAntimicrob. Agents Chemother.201559420642141:CAS:528:DC%2BC2MXhtFaqsr7M25941228446867810.1128/AAC.05030-14 SindenREDeveloping transmission-blocking strategies for malaria controlPLoS Pathog.201713e100633628683121550036510.1371/journal.ppat.1006336 TibúrcioMA switch in infected erythrocyte deformability at the maturation and blood circulation of Plasmodium falciparum transmission stagesBlood2012119e172e18022517905338294210.1182/blood-2012-03-414557 KumarADharSKSubbaraoNIn silico identification of inhibitors against Plasmodium falciparum histone deacetylase 1 (PfHDAC-1)J. Mol. Model.2018242323010944010.1007/s00894-018-3761-1 White, N. J. Emergence of artemisinin-resistant olasmodium falciparum in East Africa. N. Engl. J. Med. https://doi.org/10.1056/NEJMe2110659 (2021). SafeukuiIQuantitative assessment of sensing and sequestration of spherocytic erythrocytes by the human spleenBlood20121204244301:CAS:528:DC%2BC38XhtFCktL%2FJ22510876339876410.1182/blood-2012-01-404103 LucantoniLA simple and predictive phenotypic high content imaging assay for Plasmodium falciparum mature gametocytes to identify Malaria transmission blocking compoundsSci. Rep.201552015NatSR...516414L1:CAS:528:DC%2BC2MXhvVWmsrvF26553647463976910.1038/srep16414 Miguel-BlancoCImaging-based high-throughput screening assay to identify new molecules with transmission-blocking potential against Plasmodium falciparum female gamete formationAntimicrob. Agents Chemother.201559329833051:CAS:528:DC%2BC2MXpsFGjtLg%3D25801574443215910.1128/AAC.04684-14 DuezJHigh-throughput microsphiltration to assess red blood cell deformability and screen for malaria transmission–blocking drugsNat. Protoc.201813136213761:CAS:528:DC%2BC1cXhtVamurbM2984452410.1038/nprot.2018.035 ChavchichMVan BredaKRowcliffeKDiaganaTTEdsteinMDThe spiroindolone KAE609 does not induce dormant ring stages in Plasmodium falciparum parasitesAntimicrob. Agents Chemother.201660516751741:CAS:528:DC%2BC2sXhtlKltrY%3D27297484499787710.1128/AAC.02838-15 LambrosCVanderbergJPSynchronization of Plasmodium falciparum erythrocytic stages in cultureJ. Parasitol.1979654184201:STN:280:DyaL3c%2FgvVGmtg%3D%3D38393610.2307/3280287 MillerLHUsamiSChienSAlteration in the rheologic properties of Plasmodium knowlesi-infected red cells. A possible mechanism for capillary obstructionJ. Clin. Invest.197150145114551:STN:280:DyaE3M3jtVajtw%3D%3D499688429208410.1172/JCI106629 DuffySLoganathanSHolleranJPAveryVMLarge-scale production of Plasmodium falciparum gametocytes for malaria drug discoveryNat. Protoc.2016119769921:CAS:528:DC%2BC28XmsFaqsLg%3D2712394910.1038/nprot.2016.056 DecheringKJModelling mosquito infection at natural parasite densities identifies drugs targeting EF2, PI4K or ATP4 as key candidates for interrupting malaria transmissionSci. Rep.201772017NatSR...717680D29247222573216410.1038/s41598-017-16671-0 Pelt-KoopsJCvanThe spiroindolone drug candidate NITD609 potently inhibits gametocytogenesis and blocks Plasmodium falciparum transmission to anopheles Mosquito vectorAntimicrob. Agents Chemother.2012563544354822508309339346410.1128/AAC.06377-11 BuffetPAEx vivo perfusion of human spleens maintains clearing and processing functionsBlood2006107374537521:CAS:528:DC%2BD28Xkt1Giu7c%3D1638492710.1182/blood-2005-10-4094 BetticaPHistological effects of givinostat in boys with Duchenne muscular dystrophyNeuromuscul. Disord.2016266436492756686610.1016/j.nmd.2016.07.002 SicilianoGA high susceptibility to redox imbalance of the transmissible stages of Plasmodium falciparum revealed with a luciferase-based mature gametocyte assayMol. Microbiol.20171043063181:CAS:528:DC%2BC2sXivFers7s%3D28118506538055910.1111/mmi.13626 LiCPharmacokinetics, safety, and tolerability of Ledipasvir/Sofosbuvir and Sofosbuvir/Velpatasvir in healthy Chinese subjectsClin. Ther.2020424484571:CAS:528:DC%2BB3cXjtFelu74%3D3211524310.1016/j.clinthera.2020.01.013 Ashley, E. A. et al. Spread of Artemisinin Resistance in Plasmodium falciparum Malaria.https://doi.org/10.1056/NEJMoa1314981 (2014). Balikagala, B. et al. Evidence of artemisinin-resistant Malaria in Africa. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2101746 (2021). PaonessaGGametocyte-specific and all-blood-stage transmission-blocking chemotypes discovered from high throughput screening on Plasmodium falciparum gametocytesCommun. Biol.2022511010.1038/s42003-022-03510-w DeplaineGThe sensing of poorly deformable red blood cells by the human spleen can be mimicked in vitroBlood2011117e88e951:CAS:528:DC%2BC3MXjsVWntrg%3D21163923306241710.1182/blood-2010-10-312801 RousselCRapid clearance of storage-induced microerythrocytes alters transfusion recoveryBlood2021137228522981:CAS:528:DC%2BB3MXhtVeisbrJ33657208808548210.1182/blood.2020008563 WHO. World Malaria Report 2021. https://www.who.int/teams/global-malaria-programme/reports/world-malaria-report-2021 (2021). BurrowsJNNew developments in anti-malarial target candidate and product profilesMalar. J.20171628086874523720010.1186/s12936-016-1675-x DennisASMRoslingJEOLehaneAMKirkKDiverse antimalarials from whole-cell phenotypic screens disrupt malaria parasite ion and volume homeostasisSci. Rep.201882018NatSR...8.8795D29892073599586810.1038/s41598-018-26819-1 ZavalaFRTS,S: the first malaria vaccineJ. Clin. Invest.2022132e15658834981788871814210.1172/JCI156588 MénardDA worldwide map of Plasmodium falciparum K13-propeller polymorphismsN. Engl. J. Med.20163742453246427332904495556210.1056/NEJMoa1513137 MénardSInduction of multidrug tolerance in Plasmodium falciparum by extended artemisinin pressureEmerg. Infect. Dis.2015211733174126401601459344710.3201/eid2110.150682 AingaranMHost cell deformability is linked to transmission in the human malaria parasite Plasmodium falciparumCell. Microbiol.2012149839931:CAS:528:DC%2BC38XosFSrsrc%3D22417683337622610.1111/j.1462-5822.2012.01786.x CoulibalyBStrong gametocytocidal effect of methylene blue-based combination therapy against Falciparum Malaria: a randomised controlled trialPLoS One20094e53182009PLoSO...4.5318C19415120267358210.1371/journal.pone.0005318 GarimellaTEffects of a fixed-dose co-formulation of Daclatasvir, Asunaprevir, and Beclabuvir on the Pharmacokinetics of a cocktail of cytochrome P450 and drug transporter substrates in healthy subjectsDrugs RD201818556538733171:CAS:528:DC%2BC1cXhs1WnsA%3D%3D10.1007/s40268-017-0222-8 CranstonHAPlasmodium falciparum maturation abolishes physiologic red cell deformabilityScience19842234004031984Sci...223..400C1:STN:280:DyaL2c%2FpslGnsw%3D%3D636200710.1126/science.6362007 PlouffeDMHigh-throughput assay and discovery of small molecules that interrupt Malaria transmissionCell Host Microbe2016191141261:CAS:528:DC%2BC28XhtlKrsQ%3D%3D26749441472371610.1016/j.chom.2015.12.001 RottmannMSpiroindolones, a potent compound class for the treatment of MalariaScience2010329117511802010Sci...329.1175R1:CAS:528:DC%2BC3cXhtV2hsr%2FJ20813948305000110.1126/science.1193225 SindenREPlasmodium differentiation in the mosquitoParassitologia1999411391481:STN:280:DC%2BD3c7mt12mtg%3D%3D10697846 BuggyJJCRA-024781: a novel synthetic inhibitor of histone deacetylase enzymes with antitumor activity in vitro and in vivoMol. Cancer Ther.20065130913171:CAS:528:DC%2BD28XltVWms7Y%3D1673176410.1158/1535-7163.MCT-05-0442 D’AlessandroSA Plasmodium falciparum screening assay for anti-gametocyte drugs based on parasite lactate dehydrogenase detectionJ. Antimicrob. Chemother.201368204820582364558810.1093/jac/dkt165 GroomACSchmidtEEMacDonaldICMicrocirculatory pathways and blood flow in spleen: new insights from washout kinetics, corrosion casts, and quantitative intravital videomicroscopyScanning Microsc.199151591731:STN:280:DyaK3M3ntF2jtw%3D%3D2052921 ChappellCALedipasvir plus sofosbuvir in pregnant women with hepatitis C virus infection: a phase 1 pharmacokinetic studyLancet Microbe20201e200e2081:CAS:528:DC%2BB3cXit1Oltb7K32939459749155310.1016/S2666-5247(20)30062-8 HassanHEPharmacokinetics and safety assessment of l-tetrahydropalmatine in cocaine users: a randomized, double-blind, placebo-controlled studyJ. Clin. Pharmacol.2017571511601:CAS:528:DC%2BC2sXotlWjsQ%3D%3D2736331310.1002/jcph.789 MeibalanEPlasmodium falciparum gametocyte density and infectivity in peripheral blood and skin tissue of naturally infected parasite carriers in Burkina FasoJ. Infect. Dis.2021223182218301:CAS:528:DC%2BB3MXhtlWlurnP3187590910.1093/infdis/jiz680 ZhangJ-HChungTDYOldenburgKRA simple statistical parameter for use in evaluation and validation of high throughput screening assaysJ. Biomol. Screen.1999467731:STN:280:DC%2BC2sbit12juw%3D%3D1083841410.1177/108705719900400206 VaidyaABPyrazoleamide compounds are potent antimalarials that target Na+ home JCvan Pelt-Koops (37359_CR41) 2012; 56 RE Sinden (37359_CR8) 1999; 41 T Garimella (37359_CR55) 2018; 18 37359_CR64 JN Burrows (37359_CR7) 2017; 16 N Mohandas (37359_CR9) 1986; 68 TT Hien (37359_CR38) 2017; 61 37359_CR69 ASM Dennis (37359_CR30) 2018; 8 G Paonessa (37359_CR22) 2022; 5 37359_CR61 PA Buffet (37359_CR48) 2006; 107 C Li (37359_CR57) 2020; 42 JS McCarthy (37359_CR37) 2020; 71 M Depond (37359_CR26) 2020; 10 M-E N’Dri (37359_CR33) 2021; 244 C Lambros (37359_CR70) 1979; 65 RE Sinden (37359_CR63) 2017; 13 J Janes (37359_CR23) 2018; 115 37359_CR59 37359_CR56 J Duez (37359_CR28) 2015; 59 AC Groom (37359_CR11) 1991; 5 C Miguel-Blanco (37359_CR36) 2015; 59 KJ Dechering (37359_CR50) 2017; 7 D Ménard (37359_CR3) 2016; 374 L Lucantoni (37359_CR19) 2015; 5 B Baragaña (37359_CR49) 2015; 522 J-H Zhang (37359_CR68) 1999; 4 37359_CR1 J Duez (37359_CR27) 2018; 13 37359_CR2 37359_CR5 37359_CR6 H Noedl (37359_CR4) 2009; 361 I Safeukui (37359_CR12) 2012; 120 HE Hassan (37359_CR42) 2017; 57 W Trager (37359_CR65) 1976; 193 HA Cranston (37359_CR14) 1984; 223 B Coulibaly (37359_CR34) 2009; 4 HM Malebo (37359_CR43) 2013; 13 AB Vaidya (37359_CR54) 2014; 5 S Ménard (37359_CR45) 2015; 21 J Calit (37359_CR29) 2018; 62 I Safeukui (37359_CR10) 2008; 112 M Aingaran (37359_CR13) 2012; 14 S Duffy (37359_CR66) 2016; 11 MJ Delves (37359_CR18) 2018; 9 P Bettica (37359_CR52) 2016; 26 MJ Almela (37359_CR17) 2015; 10 G Deplaine (37359_CR25) 2011; 117 F Zavala (37359_CR62) 2022; 132 J Lotharius (37359_CR24) 2014; 13 G Siciliano (37359_CR67) 2017; 104 E Meibalan (37359_CR60) 2021; 223 B Naissant (37359_CR32) 2016; 127 DM Plouffe (37359_CR20) 2016; 19 M Chavchich (37359_CR44) 2016; 60 S D’Alessandro (37359_CR35) 2013; 68 P Jagannathan (37359_CR47) 2022; 13 C Roussel (37359_CR46) 2021; 137 V Potluri (37359_CR21) 2020; 19 A Kumar (37359_CR53) 2018; 24 S Duffy (37359_CR31) 2013; 12 JJ Buggy (37359_CR51) 2006; 5 CA Chappell (37359_CR58) 2020; 1 R Zhang (37359_CR40) 2016; 213 LH Miller (37359_CR15) 1971; 50 M Tibúrcio (37359_CR16) 2012; 119 M Rottmann (37359_CR39) 2010; 329 |
| References_xml | – reference: JanesJThe ReFRAME library as a comprehensive drug repurposing library and its application to the treatment of cryptosporidiosisProc. Natl Acad. Sci. USA201811510750107552018PNAS..11510750J1:CAS:528:DC%2BC1cXhvFynsbfJ30282735619652610.1073/pnas.1810137115 – reference: HassanHEPharmacokinetics and safety assessment of l-tetrahydropalmatine in cocaine users: a randomized, double-blind, placebo-controlled studyJ. Clin. Pharmacol.2017571511601:CAS:528:DC%2BC2sXotlWjsQ%3D%3D2736331310.1002/jcph.789 – reference: SindenREDeveloping transmission-blocking strategies for malaria controlPLoS Pathog.201713e100633628683121550036510.1371/journal.ppat.1006336 – reference: SicilianoGA high susceptibility to redox imbalance of the transmissible stages of Plasmodium falciparum revealed with a luciferase-based mature gametocyte assayMol. Microbiol.20171043063181:CAS:528:DC%2BC2sXivFers7s%3D28118506538055910.1111/mmi.13626 – reference: HienTTEstimation of the in vivo MIC of Cipargamin in uncomplicated Plasmodium falciparum MalariaAntimicrob. Agents Chemother.201761e01940161:CAS:528:DC%2BC2sXpsF2lsb8%3D27872070527873010.1128/AAC.01940-16 – reference: DuezJHigh-throughput microsphiltration to assess red blood cell deformability and screen for malaria transmission–blocking drugsNat. Protoc.201813136213761:CAS:528:DC%2BC1cXhtVamurbM2984452410.1038/nprot.2018.035 – reference: MeibalanEPlasmodium falciparum gametocyte density and infectivity in peripheral blood and skin tissue of naturally infected parasite carriers in Burkina FasoJ. Infect. Dis.2021223182218301:CAS:528:DC%2BB3MXhtlWlurnP3187590910.1093/infdis/jiz680 – reference: SafeukuiIRetention of Plasmodium falciparum ring-infected erythrocytes in the slow, open microcirculation of the human spleenBlood2008112252025281:CAS:528:DC%2BD1cXhtFCru73M1857979610.1182/blood-2008-03-146779 – reference: Balikagala, B. et al. Evidence of artemisinin-resistant Malaria in Africa. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2101746 (2021). – reference: DelvesMJA high throughput screen for next-generation leads targeting malaria parasite transmissionNat. Commun.201892018NatCo...9.3805D30228275614362510.1038/s41467-018-05777-2 – reference: RottmannMSpiroindolones, a potent compound class for the treatment of MalariaScience2010329117511802010Sci...329.1175R1:CAS:528:DC%2BC3cXhtV2hsr%2FJ20813948305000110.1126/science.1193225 – reference: MaleboHMAnti-protozoal activity of aporphine and protoberberine alkaloids from Annickia kummeriae (Engl. & Diels) Setten & Maas (Annonaceae)BMC Complement. Altern. Med.201313481:CAS:528:DC%2BC3sXmt1Gks7g%3D23445637359982210.1186/1472-6882-13-48 – reference: LothariusJRepositioning: the fast track to new anti-malarial medicines?Malar. J.20141324731288402120110.1186/1475-2875-13-143 – reference: DuffySAveryVMIdentification of inhibitors of Plasmodium falciparum gametocyte developmentMalar. J.20131224206914384268410.1186/1475-2875-12-408 – reference: AingaranMHost cell deformability is linked to transmission in the human malaria parasite Plasmodium falciparumCell. Microbiol.2012149839931:CAS:528:DC%2BC38XosFSrsrc%3D22417683337622610.1111/j.1462-5822.2012.01786.x – reference: BuffetPAEx vivo perfusion of human spleens maintains clearing and processing functionsBlood2006107374537521:CAS:528:DC%2BD28Xkt1Giu7c%3D1638492710.1182/blood-2005-10-4094 – reference: CoulibalyBStrong gametocytocidal effect of methylene blue-based combination therapy against Falciparum Malaria: a randomised controlled trialPLoS One20094e53182009PLoSO...4.5318C19415120267358210.1371/journal.pone.0005318 – reference: ChappellCALedipasvir plus sofosbuvir in pregnant women with hepatitis C virus infection: a phase 1 pharmacokinetic studyLancet Microbe20201e200e2081:CAS:528:DC%2BB3cXit1Oltb7K32939459749155310.1016/S2666-5247(20)30062-8 – reference: Delves, M. J. et al. Male and female Plasmodium falciparum mature gametocytes show different responses to antimalarial drugs. Antimicrob. Agents Chemother. https://doi.org/10.1128/AAC.00325-13 (2013). – reference: White, N. J. Emergence of artemisinin-resistant olasmodium falciparum in East Africa. N. Engl. J. Med. https://doi.org/10.1056/NEJMe2110659 (2021). – reference: N’DriM-ERoyerLLavazecCTadalafil impacts the mechanical properties of Plasmodium falciparum gametocyte-infected erythrocytesMol. Biochem. Parasitol.20212441113923417145610.1016/j.molbiopara.2021.111392 – reference: JagannathanPKakuruAMalaria in 2022: increasing challenges, cautious optimismNat. Commun.2022132022NatCo..13.2678J1:CAS:528:DC%2BB38Xht12mu7jP35562368910672710.1038/s41467-022-30133-w – reference: TragerWJensenJBHuman malaria parasites in continuous cultureScience19761936736751976Sci...193..673T1:STN:280:DyaE283ks1Wqug%3D%3D78184010.1126/science.781840 – reference: VaidyaABPyrazoleamide compounds are potent antimalarials that target Na+ homeostasis in intraerythrocytic Plasmodium falciparumNat. Commun.201452014NatCo...5.5521V1:CAS:528:DC%2BC2MXjvFWqtrs%3D2542285310.1038/ncomms6521 – reference: RousselCRapid clearance of storage-induced microerythrocytes alters transfusion recoveryBlood2021137228522981:CAS:528:DC%2BB3MXhtVeisbrJ33657208808548210.1182/blood.2020008563 – reference: DuffySLoganathanSHolleranJPAveryVMLarge-scale production of Plasmodium falciparum gametocytes for malaria drug discoveryNat. Protoc.2016119769921:CAS:528:DC%2BC28XmsFaqsLg%3D2712394910.1038/nprot.2016.056 – reference: Stone, W. et al. Single low-dose tafenoquine combined with dihydroartemisinin–piperaquine to reduce Plasmodium falciparum transmission in Ouelessebougou, Mali: a phase 2, single-blind, randomised clinical trial. Lancet Microbe3, e336–e347 (2022). – reference: ChavchichMVan BredaKRowcliffeKDiaganaTTEdsteinMDThe spiroindolone KAE609 does not induce dormant ring stages in Plasmodium falciparum parasitesAntimicrob. Agents Chemother.201660516751741:CAS:528:DC%2BC2sXhtlKltrY%3D27297484499787710.1128/AAC.02838-15 – reference: BuggyJJCRA-024781: a novel synthetic inhibitor of histone deacetylase enzymes with antitumor activity in vitro and in vivoMol. Cancer Ther.20065130913171:CAS:528:DC%2BD28XltVWms7Y%3D1673176410.1158/1535-7163.MCT-05-0442 – reference: PaonessaGGametocyte-specific and all-blood-stage transmission-blocking chemotypes discovered from high throughput screening on Plasmodium falciparum gametocytesCommun. Biol.2022511010.1038/s42003-022-03510-w – reference: DennisASMRoslingJEOLehaneAMKirkKDiverse antimalarials from whole-cell phenotypic screens disrupt malaria parasite ion and volume homeostasisSci. Rep.201882018NatSR...8.8795D29892073599586810.1038/s41598-018-26819-1 – reference: NaissantBPlasmodium falciparum STEVOR phosphorylation regulates host erythrocyte deformability enabling malaria parasite transmissionBlood2016127e42e531:CAS:528:DC%2BC28Xhs1entL%2FJ2713694510.1182/blood-2016-01-690776 – reference: AlmelaMJA new set of chemical starting points with Plasmodium falciparum transmission-blocking potential for antimalarial drug discoveryPLoS One201510e013513926317851455263410.1371/journal.pone.0135139 – reference: Mogalian, E. et al. Preclinical Pharmacokinetics and first-in-human Pharmacokinetics, safety, and tolerability of Velpatasvir, a Pangenotypic Hepatitis C virus NS5A inhibitor, in healthy subjects. Antimicrob. Agents Chemother. 61, e02084-16 (2017). – reference: LambrosCVanderbergJPSynchronization of Plasmodium falciparum erythrocytic stages in cultureJ. Parasitol.1979654184201:STN:280:DyaL3c%2FgvVGmtg%3D%3D38393610.2307/3280287 – reference: WHO. World Malaria Report 2021. https://www.who.int/teams/global-malaria-programme/reports/world-malaria-report-2021 (2021). – reference: SindenREPlasmodium differentiation in the mosquitoParassitologia1999411391481:STN:280:DC%2BD3c7mt12mtg%3D%3D10697846 – reference: BetticaPHistological effects of givinostat in boys with Duchenne muscular dystrophyNeuromuscul. Disord.2016266436492756686610.1016/j.nmd.2016.07.002 – reference: Lengeler, C. Insecticide‐treated bed nets and curtains for preventing malaria. Cochrane Database Syst. Rev. https://doi.org/10.1002/14651858.CD000363.pub2 (2004). – reference: ZhangJ-HChungTDYOldenburgKRA simple statistical parameter for use in evaluation and validation of high throughput screening assaysJ. Biomol. Screen.1999467731:STN:280:DC%2BC2sbit12juw%3D%3D1083841410.1177/108705719900400206 – reference: DepondMHenryBBuffetPNdourPAMethods to investigate the deformability of RBC during MalariaFront. Physiol.202010161332038293699012210.3389/fphys.2019.01613 – reference: DeplaineGThe sensing of poorly deformable red blood cells by the human spleen can be mimicked in vitroBlood2011117e88e951:CAS:528:DC%2BC3MXjsVWntrg%3D21163923306241710.1182/blood-2010-10-312801 – reference: Pelt-KoopsJCvanThe spiroindolone drug candidate NITD609 potently inhibits gametocytogenesis and blocks Plasmodium falciparum transmission to anopheles Mosquito vectorAntimicrob. Agents Chemother.2012563544354822508309339346410.1128/AAC.06377-11 – reference: Lavazec, C. et al. in Malaria: Methods and Protocols (ed. Ménard, R.) 291–297 (Humana Press, 2013). – reference: CranstonHAPlasmodium falciparum maturation abolishes physiologic red cell deformabilityScience19842234004031984Sci...223..400C1:STN:280:DyaL2c%2FpslGnsw%3D%3D636200710.1126/science.6362007 – reference: D’AlessandroSA Plasmodium falciparum screening assay for anti-gametocyte drugs based on parasite lactate dehydrogenase detectionJ. Antimicrob. Chemother.201368204820582364558810.1093/jac/dkt165 – reference: BaragañaBA novel multiple-stage antimalarial agent that inhibits protein synthesisNature20155223153202015Natur.522..315B26085270470093010.1038/nature14451 – reference: LucantoniLA simple and predictive phenotypic high content imaging assay for Plasmodium falciparum mature gametocytes to identify Malaria transmission blocking compoundsSci. Rep.201552015NatSR...516414L1:CAS:528:DC%2BC2MXhvVWmsrvF26553647463976910.1038/srep16414 – reference: ZavalaFRTS,S: the first malaria vaccineJ. Clin. Invest.2022132e15658834981788871814210.1172/JCI156588 – reference: PlouffeDMHigh-throughput assay and discovery of small molecules that interrupt Malaria transmissionCell Host Microbe2016191141261:CAS:528:DC%2BC28XhtlKrsQ%3D%3D26749441472371610.1016/j.chom.2015.12.001 – reference: BurrowsJNNew developments in anti-malarial target candidate and product profilesMalar. J.20171628086874523720010.1186/s12936-016-1675-x – reference: ZhangRA basis for rapid clearance of circulating ring-stage Malaria parasites by the spiroindolone KAE609J. Infect. Dis.20162131001042016sdeg.book.....Z1:CAS:528:DC%2BC1cXktFequ7s%3D2613647210.1093/infdis/jiv358 – reference: DuezJSplenic retention of Plasmodium falciparum gametocytes to block the transmission of MalariaAntimicrob. Agents Chemother.201559420642141:CAS:528:DC%2BC2MXhtFaqsr7M25941228446867810.1128/AAC.05030-14 – reference: McCarthyJSA Phase 1, Placebo-controlled, randomized, single ascending dose study and a volunteer infection study to characterize the safety, pharmacokinetics, and antimalarial activity of the Plasmodium phosphatidylinositol 4-kinase inhibitor MMV390048Clin. Infect. Dis.202071e657e6641:CAS:528:DC%2BB3MXnvFCitQ%3D%3D32239164774498610.1093/cid/ciaa368 – reference: GarimellaTEffects of a fixed-dose co-formulation of Daclatasvir, Asunaprevir, and Beclabuvir on the Pharmacokinetics of a cocktail of cytochrome P450 and drug transporter substrates in healthy subjectsDrugs RD201818556538733171:CAS:528:DC%2BC1cXhs1WnsA%3D%3D10.1007/s40268-017-0222-8 – reference: MillerLHUsamiSChienSAlteration in the rheologic properties of Plasmodium knowlesi-infected red cells. A possible mechanism for capillary obstructionJ. Clin. Invest.197150145114551:STN:280:DyaE3M3jtVajtw%3D%3D499688429208410.1172/JCI106629 – reference: NoedlHSocheatDSatimaiWArtemisinin-resistant malaria in AsiaN. Engl. J. Med.20093615405411:CAS:528:DC%2BD1MXpt1eqt70%3D1964121910.1056/NEJMc0900231 – reference: Miguel-BlancoCImaging-based high-throughput screening assay to identify new molecules with transmission-blocking potential against Plasmodium falciparum female gamete formationAntimicrob. Agents Chemother.201559329833051:CAS:528:DC%2BC2MXpsFGjtLg%3D25801574443215910.1128/AAC.04684-14 – reference: PotluriVDiscovery of FNDR-20123, a histone deacetylase inhibitor for the treatment of Plasmodium falciparum malariaMalar. J.2020191:CAS:528:DC%2BB3cXitVGqt7%2FJ33046062754921410.1186/s12936-020-03421-3 – reference: SafeukuiIQuantitative assessment of sensing and sequestration of spherocytic erythrocytes by the human spleenBlood20121204244301:CAS:528:DC%2BC38XhtFCktL%2FJ22510876339876410.1182/blood-2012-01-404103 – reference: MohandasNRossiMEClarkMRAssociation between morphologic distortion of sickle cells and deoxygenation-induced cation permeability increaseBlood1986684504541:CAS:528:DyaL28XkvFGnurw%3D373060910.1182/blood.V68.2.450.450 – reference: MénardSInduction of multidrug tolerance in Plasmodium falciparum by extended artemisinin pressureEmerg. Infect. Dis.2015211733174126401601459344710.3201/eid2110.150682 – reference: KumarADharSKSubbaraoNIn silico identification of inhibitors against Plasmodium falciparum histone deacetylase 1 (PfHDAC-1)J. Mol. Model.2018242323010944010.1007/s00894-018-3761-1 – reference: GroomACSchmidtEEMacDonaldICMicrocirculatory pathways and blood flow in spleen: new insights from washout kinetics, corrosion casts, and quantitative intravital videomicroscopyScanning Microsc.199151591731:STN:280:DyaK3M3ntF2jtw%3D%3D2052921 – reference: LiCPharmacokinetics, safety, and tolerability of Ledipasvir/Sofosbuvir and Sofosbuvir/Velpatasvir in healthy Chinese subjectsClin. Ther.2020424484571:CAS:528:DC%2BB3cXjtFelu74%3D3211524310.1016/j.clinthera.2020.01.013 – reference: CalitJScreening the pathogen box for molecules active against Plasmodium sexual stages using a new nanoluciferase-based transgenic line of P. berghei Identifies transmission-blocking compoundsAntimicrob. Agents Chemother.201862e010531830181368620111910.1128/AAC.01053-18 – reference: TibúrcioMA switch in infected erythrocyte deformability at the maturation and blood circulation of Plasmodium falciparum transmission stagesBlood2012119e172e18022517905338294210.1182/blood-2012-03-414557 – reference: Ashley, E. A. et al. Spread of Artemisinin Resistance in Plasmodium falciparum Malaria.https://doi.org/10.1056/NEJMoa1314981 (2014). – reference: MénardDA worldwide map of Plasmodium falciparum K13-propeller polymorphismsN. Engl. J. Med.20163742453246427332904495556210.1056/NEJMoa1513137 – reference: DecheringKJModelling mosquito infection at natural parasite densities identifies drugs targeting EF2, PI4K or ATP4 as key candidates for interrupting malaria transmissionSci. Rep.201772017NatSR...717680D29247222573216410.1038/s41598-017-16671-0 – volume: 19 start-page: 114 year: 2016 ident: 37359_CR20 publication-title: Cell Host Microbe doi: 10.1016/j.chom.2015.12.001 – volume: 13 year: 2014 ident: 37359_CR24 publication-title: Malar. J. doi: 10.1186/1475-2875-13-143 – volume: 65 start-page: 418 year: 1979 ident: 37359_CR70 publication-title: J. Parasitol. doi: 10.2307/3280287 – volume: 115 start-page: 10750 year: 2018 ident: 37359_CR23 publication-title: Proc. Natl Acad. Sci. USA doi: 10.1073/pnas.1810137115 – ident: 37359_CR61 doi: 10.1002/14651858.CD000363.pub2 – volume: 127 start-page: e42 year: 2016 ident: 37359_CR32 publication-title: Blood doi: 10.1182/blood-2016-01-690776 – volume: 71 start-page: e657 year: 2020 ident: 37359_CR37 publication-title: Clin. Infect. Dis. doi: 10.1093/cid/ciaa368 – volume: 11 start-page: 976 year: 2016 ident: 37359_CR66 publication-title: Nat. Protoc. doi: 10.1038/nprot.2016.056 – volume: 5 start-page: 1 year: 2022 ident: 37359_CR22 publication-title: Commun. Biol. doi: 10.1038/s42003-022-03510-w – volume: 244 start-page: 111392 year: 2021 ident: 37359_CR33 publication-title: Mol. Biochem. Parasitol. doi: 10.1016/j.molbiopara.2021.111392 – volume: 522 start-page: 315 year: 2015 ident: 37359_CR49 publication-title: Nature doi: 10.1038/nature14451 – volume: 56 start-page: 3544 year: 2012 ident: 37359_CR41 publication-title: Antimicrob. Agents Chemother. doi: 10.1128/AAC.06377-11 – volume: 26 start-page: 643 year: 2016 ident: 37359_CR52 publication-title: Neuromuscul. Disord. doi: 10.1016/j.nmd.2016.07.002 – volume: 18 start-page: 55 year: 2018 ident: 37359_CR55 publication-title: Drugs RD doi: 10.1007/s40268-017-0222-8 – ident: 37359_CR69 doi: 10.1007/978-1-62703-026-7_20 – volume: 4 start-page: e5318 year: 2009 ident: 37359_CR34 publication-title: PLoS One doi: 10.1371/journal.pone.0005318 – ident: 37359_CR59 doi: 10.1128/AAC.00325-13 – volume: 5 start-page: 1309 year: 2006 ident: 37359_CR51 publication-title: Mol. Cancer Ther. doi: 10.1158/1535-7163.MCT-05-0442 – volume: 1 start-page: e200 year: 2020 ident: 37359_CR58 publication-title: Lancet Microbe doi: 10.1016/S2666-5247(20)30062-8 – volume: 120 start-page: 424 year: 2012 ident: 37359_CR12 publication-title: Blood doi: 10.1182/blood-2012-01-404103 – volume: 13 start-page: e1006336 year: 2017 ident: 37359_CR63 publication-title: PLoS Pathog. doi: 10.1371/journal.ppat.1006336 – volume: 119 start-page: e172 year: 2012 ident: 37359_CR16 publication-title: Blood doi: 10.1182/blood-2012-03-414557 – ident: 37359_CR6 doi: 10.1056/NEJMe2110659 – volume: 59 start-page: 3298 year: 2015 ident: 37359_CR36 publication-title: Antimicrob. Agents Chemother. doi: 10.1128/AAC.04684-14 – volume: 41 start-page: 139 year: 1999 ident: 37359_CR8 publication-title: Parassitologia – volume: 223 start-page: 400 year: 1984 ident: 37359_CR14 publication-title: Science doi: 10.1126/science.6362007 – volume: 50 start-page: 1451 year: 1971 ident: 37359_CR15 publication-title: J. Clin. Invest. doi: 10.1172/JCI106629 – volume: 13 start-page: 1362 year: 2018 ident: 37359_CR27 publication-title: Nat. Protoc. doi: 10.1038/nprot.2018.035 – volume: 57 start-page: 151 year: 2017 ident: 37359_CR42 publication-title: J. Clin. Pharmacol. doi: 10.1002/jcph.789 – volume: 21 start-page: 1733 year: 2015 ident: 37359_CR45 publication-title: Emerg. Infect. Dis. doi: 10.3201/eid2110.150682 – volume: 117 start-page: e88 year: 2011 ident: 37359_CR25 publication-title: Blood doi: 10.1182/blood-2010-10-312801 – ident: 37359_CR64 doi: 10.1016/S2666-5247(21)00356-6 – volume: 193 start-page: 673 year: 1976 ident: 37359_CR65 publication-title: Science doi: 10.1126/science.781840 – volume: 61 start-page: e01940 year: 2017 ident: 37359_CR38 publication-title: Antimicrob. Agents Chemother. doi: 10.1128/AAC.01940-16 – volume: 68 start-page: 450 year: 1986 ident: 37359_CR9 publication-title: Blood doi: 10.1182/blood.V68.2.450.450 – volume: 5 year: 2014 ident: 37359_CR54 publication-title: Nat. Commun. doi: 10.1038/ncomms6521 – ident: 37359_CR56 doi: 10.1128/AAC.02084-16 – volume: 104 start-page: 306 year: 2017 ident: 37359_CR67 publication-title: Mol. Microbiol. doi: 10.1111/mmi.13626 – volume: 9 year: 2018 ident: 37359_CR18 publication-title: Nat. Commun. doi: 10.1038/s41467-018-05777-2 – volume: 374 start-page: 2453 year: 2016 ident: 37359_CR3 publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1513137 – volume: 213 start-page: 100 year: 2016 ident: 37359_CR40 publication-title: J. Infect. Dis. doi: 10.1093/infdis/jiv358 – volume: 7 year: 2017 ident: 37359_CR50 publication-title: Sci. Rep. doi: 10.1038/s41598-017-16671-0 – ident: 37359_CR1 – volume: 10 start-page: 1613 year: 2020 ident: 37359_CR26 publication-title: Front. Physiol. doi: 10.3389/fphys.2019.01613 – ident: 37359_CR5 doi: 10.1056/NEJMoa2101746 – volume: 5 start-page: 159 year: 1991 ident: 37359_CR11 publication-title: Scanning Microsc. – volume: 329 start-page: 1175 year: 2010 ident: 37359_CR39 publication-title: Science doi: 10.1126/science.1193225 – volume: 223 start-page: 1822 year: 2021 ident: 37359_CR60 publication-title: J. Infect. Dis. doi: 10.1093/infdis/jiz680 – volume: 361 start-page: 540 year: 2009 ident: 37359_CR4 publication-title: N. Engl. J. Med. doi: 10.1056/NEJMc0900231 – volume: 107 start-page: 3745 year: 2006 ident: 37359_CR48 publication-title: Blood doi: 10.1182/blood-2005-10-4094 – volume: 112 start-page: 2520 year: 2008 ident: 37359_CR10 publication-title: Blood doi: 10.1182/blood-2008-03-146779 – ident: 37359_CR2 doi: 10.1056/NEJMoa1314981 – volume: 132 start-page: e156588 year: 2022 ident: 37359_CR62 publication-title: J. Clin. Invest. doi: 10.1172/JCI156588 – volume: 14 start-page: 983 year: 2012 ident: 37359_CR13 publication-title: Cell. Microbiol. doi: 10.1111/j.1462-5822.2012.01786.x – volume: 13 start-page: 48 year: 2013 ident: 37359_CR43 publication-title: BMC Complement. Altern. Med. doi: 10.1186/1472-6882-13-48 – volume: 24 start-page: 232 year: 2018 ident: 37359_CR53 publication-title: J. Mol. Model. doi: 10.1007/s00894-018-3761-1 – volume: 60 start-page: 5167 year: 2016 ident: 37359_CR44 publication-title: Antimicrob. Agents Chemother. doi: 10.1128/AAC.02838-15 – volume: 4 start-page: 67 year: 1999 ident: 37359_CR68 publication-title: J. Biomol. Screen. doi: 10.1177/108705719900400206 – volume: 10 start-page: e0135139 year: 2015 ident: 37359_CR17 publication-title: PLoS One doi: 10.1371/journal.pone.0135139 – volume: 62 start-page: e01053 year: 2018 ident: 37359_CR29 publication-title: Antimicrob. Agents Chemother. doi: 10.1128/AAC.01053-18 – volume: 5 year: 2015 ident: 37359_CR19 publication-title: Sci. Rep. doi: 10.1038/srep16414 – volume: 12 year: 2013 ident: 37359_CR31 publication-title: Malar. J. doi: 10.1186/1475-2875-12-408 – volume: 16 year: 2017 ident: 37359_CR7 publication-title: Malar. J. doi: 10.1186/s12936-016-1675-x – volume: 68 start-page: 2048 year: 2013 ident: 37359_CR35 publication-title: J. Antimicrob. Chemother. doi: 10.1093/jac/dkt165 – volume: 13 year: 2022 ident: 37359_CR47 publication-title: Nat. Commun. doi: 10.1038/s41467-022-30133-w – volume: 42 start-page: 448 year: 2020 ident: 37359_CR57 publication-title: Clin. Ther. doi: 10.1016/j.clinthera.2020.01.013 – volume: 137 start-page: 2285 year: 2021 ident: 37359_CR46 publication-title: Blood doi: 10.1182/blood.2020008563 – volume: 59 start-page: 4206 year: 2015 ident: 37359_CR28 publication-title: Antimicrob. Agents Chemother. doi: 10.1128/AAC.05030-14 – volume: 8 year: 2018 ident: 37359_CR30 publication-title: Sci. Rep. doi: 10.1038/s41598-018-26819-1 – volume: 19 year: 2020 ident: 37359_CR21 publication-title: Malar. J. doi: 10.1186/s12936-020-03421-3 |
| SSID | ssj0000391844 |
| Score | 2.4570951 |
| Snippet | Malaria parasites like
Plasmodium falciparum
multiply in red blood cells (RBC), which are cleared from the bloodstream by the spleen when their deformability... Malaria parasites like Plasmodium falciparum multiply in red blood cells (RBC), which are cleared from the bloodstream by the spleen when their deformability... Authors propose their splenic mimetic filtration method, microsphiltration, and utilise this approach in a drug-screen, to identify compounds that induce a... |
| SourceID | doaj pubmedcentral proquest pubmed crossref springer |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 1951 |
| SubjectTerms | 13 13/31 14 14/19 14/34 14/63 49 49/47 631/154/1435/2163 631/326/417/1716 Antimalarials - pharmacology Blocking Clinical trials Deformability Disease transmission Drugs Erythrocytes Erythrocytes - parasitology Formability Hepatitis C Humanities and Social Sciences Humans Inhibitors Malaria Malaria, Falciparum - parasitology multidisciplinary Oral administration Parasites Pharmacokinetics Plasmodium falciparum Safety Science Science (multidisciplinary) Screening Spleen Stiffening Vector-borne diseases |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQpUpcEOUZKMhI3CCq40diH9uKqkKCC1TqzbKdCaxgs6tu9tB_3xknu3R5XrhEm7WjjObhmbEn3zD22kqlY5SpJKCQUkeHJmUNlNCppm0xAkgdJYofPtbnF_r9pbm81eqLasJGeOCRcUeVrJ1tdbKutbpLlesAf0nAV0fT5X61UjhxK5nKa7BymLro6SsZoezRSuc1AV0U2pQyrpQ7nigD9v8uyvy1WPKnE9PsiM7us3tTBMmPR8oP2B3oH7D9safk9UOWPoUOeHu1_rLitMnKCZCYLxcDlQXhc8OCR3Rg3_g8YFI7C3wgb4XSpm0zToBO6DJaHq954KslFVqU89mcPnXkuMLgLRL1iF2cvft8el5OnRTKZHQ1kCnIBmTd1gndd4gS0xgtQpIRVHCmEZBMF40DI1QCgxwWGiorOlAYH-H1MdvrFz08ZbxBtrdChlTXjcbgMWCAUNkATtI2CoiCVRuu-jTBjFO3i-8-H3cr60dJeJSEz5LwsmBvts8sR5CNv84-IWFtZxJAdv4D1cZPauP_pTYFO9yI2k9Wu_KyweyqdkLj8KvtMEqADlFCD4t1noM5pkEvXrAno2ZsKVGNkK6SSKHd0ZkdUndH-tnXjOldZej9qi7Y2416_aDrz7x49j948ZzdlWQXVI_UHLK94WoNLzDUGuLLbFU3vRokyw priority: 102 providerName: Directory of Open Access Journals – databaseName: ProQuest Technology Collection dbid: 8FG link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwELagCIkL4k1oQUbiBlHjV2KfECCWCgkuUKk3y3acsoJNlk320H_fGSebann0EimxI00yM56Hx98Q8kpzIb3nIUegkFx6AyqlVcxjI6q6Bg8gNBgofvlanpzKz2fqbEq49VNZ5W5NTAt13QXMkR_zCjxfCOWkeLv-nWPXKNxdnVpo3CS3GFgalHO9-DTnWBD9XEs5nZUphD7uZVoZwFCBZgllcr5njxJs_798zb9LJv_YN03maHGP3J38SPpuZPx9ciO2D8jtsbPkxUMSvrkm0nqzPe8pplopwhLTdTdgcRC8N3TUgxn7SVcOQtulowPaLOA5Js8owjqB4aipv6CO9msst8hXyxUeeKSwzsAtEPWInC4-fv9wkk_9FPKgJBtQIXgVeVmXAYy48xyCGVm4wH0UzqiqiEE1XpmoChGiiqYuZGS6aKIALwmuj8lB27XxKaFV8KouuAtlWUlwIR24CUy7aDgmU2KREbb7qzZMYOPY8-KXTZveQtuRExY4YRMnLM_I6_md9Qi1ce3s98iseSbCZKcH3ebcTlpnQSiMrmXQptayCcw08FGaR5BbrxomMnK0Y7WddLe3V5KWkZfzMHAAt1JcG7ttmgORpgJbnpEno2TMlIiq4IZxoFDvycweqfsj7fJHQvZmCYCflRl5sxOvK7r-_y-eXf8Zh-QOR4nHeqPqiBwMm218Dq7U4F8kfbkEcaUbTQ priority: 102 providerName: ProQuest – databaseName: HAS SpringerNature Open Access 2022 dbid: AAJSJ link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1La9wwEBZhQ6GX0qQvt2lQoLfWVE9bOm5KQ1hoLmkgNyHJcrq0ay-73kP-fUfyo2ybFnoxrCXBrGdG34w0-oTQO8W4cI75PBKF5MJpcCklQx5qXlYVRAC-jonil6vi8kYsbuXtAWLjWZhUtJ8oLdM0PVaHfdyK5NKAMOASXOocpt1DBfDHZuhwPl9cL6aVlch5roQYTsgQrh4YvIdCiaz_oQjzz0LJ33ZLEwhdPEVPhugRz3t5j9BBaI7Ro_4-yftnyF_bOuBqs7vb4rjAiiMZMV63XSwJgnFdix2A13e8spDQLi3uIlKBpuOSGY5kTgAXFXb32OLtOhZZ5KvlKh5zxDC7wE8Q6jm6ufj89dNlPtyikHspaBfdgJWBFVXhAbqtY5DCCGI9c4FbLUsSvKyd1EES7oMMuiIiUEXqwCE2gucLNGvaJrxCuPROVoRZXxSlgMDRQnBAlQ2axSWUQDJEx69q_EAxHm-6-GHSVjdXpteEAU2YpAnDMvR-GrPuCTb-2fs8KmvqGcmx04t2c2cGYzGUFVpVwitdKVF7qmv4U4oFsFYna8ozdDKq2gweuzWshMyq0ERA89nUDBqIGyi2Ce0u9YH8UgKCZ-hlbxmTJLwkTFMGEqo9m9kTdb-lWX5LfN400e7TIkMfRvP6Jdffv8Xr_-v-Bj1m0QNi1VF5gmbdZhfeQkDVudPBg34CS80abA priority: 102 providerName: Springer Nature |
| Title | Safe drugs with high potential to block malaria transmission revealed by a spleen-mimetic screening |
| URI | https://link.springer.com/article/10.1038/s41467-023-37359-2 https://www.ncbi.nlm.nih.gov/pubmed/37029122 https://www.proquest.com/docview/2797469043 https://www.proquest.com/docview/2798715299 https://pubmed.ncbi.nlm.nih.gov/PMC10082216 https://doaj.org/article/12698d4c89d84fc19fe9d82eeccb5f13 |
| Volume | 14 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3db9MwELfGJiReEN8URmUk3iAQfyX2A0JdtTJV2oQYlfoW2Y4zKtYP2lSi_z13TlpUGIiXRLGd6OK78-_OH3eEvNJcSOe4TzBQSCKdAZXSKiShEnlZggXgK3QUzy-ys5EcjtX4gGzTHbUduLrRtcN8UqPl9dsf3zcfQOHfN0fG9buVjOoO6APqIpRJYEg-AmTK0Bk7b839ODILAw4NLjTzVLIEsFu052hu_sweVsWQ_jfZoX9up_xtTTVC1eAeudvamLTXCMV9chBmD8jtJuvk5iHxl7YKtFyur1YUp2Ephiymi3mNG4fgvXpOHUDcNzq10DcTS2vEM5AHnFijGPIJQKWkbkMtXS1wK0YynUzxMCSFMQgegahHZDQ4_dI_S9pcC4lXktWoLDwPPCszDwBvHQdHR6bWcxeENSpPg1eVUyaoVPiggilTGZhOqyDAgoLrY3I4m8_CU0Jz71SZcuuzLJdgXlowIZi2wXCcaAlph7Btrxa-DUSO-TCui7ggLnTRcKIAThSREwXvkNe7dxZNGI5_tj5BZu1aYgjtWDBfXhWtRhaMZ0aX0mtTall5Zir4Kc0DyLRTFRMdcrxldbEVy4Ln4H9lJpVQ_XJXDRzAZRY7C_N1bANeqAKc75AnjWTsKBF5yg3jQKHek5k9UvdrZpOvMeo3i8H5WdYhb7bi9Yuuv_fFs_-g8zm5w1HscUNSfkwO6-U6vABbq3Zdcisf53DVg49dctTrDS-HcD85vfj0GUr7Wb8bZzG6UdF-AublKSc |
| linkProvider | Scholars Portal |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELZKEYIL4lkCBYwEJ4ia-JE4B4R4VVv6uNBKezO245QV3c12Nyu0f4rfyIyTbLU8eusl0ibOauKZ8XwzHs8Q8lIxLqxlLsZCIbGwBaiUkj72Fc_LEhCAq9BRPDzKBifiy1AON8iv_iwMplX2a2JYqMvaYYx8h-WAfMGVE_zd9DzGrlG4u9q30GjFYt8vf4LLNn-79wn4-4qx3c_HHwdx11UgdlKkDYoFyz3LysyBKTOWAaQXiXHMem4KmSfeycrKwsuEOy99USbCpyqpPAesAFf432vkusDIOOhPPsxXMR2stq6E6M7mJFztzEVYicAwgiZzWcRszf6FNgH_wrZ_p2j-sU8bzN_uHXK7w630fStod8mGn9wjN9pOlsv7xH01laflbHE6pxjapVgGmU7rBpOR4L2mphbM5g86NuBKjwxt0EaCjGGwjmIZKTBUJbVLauh8iukd8Xg0xgOWFNY1-AlEPSAnVzLTD8nmpJ74R4TmzsoyYcZlWS4AshqAJakyvmAYvPFJRNJ-VrXriptjj40zHTbZudItJzRwQgdOaBaR16t3pm1pj0tHf0BmrUZiWe5wo56d6k7LdcqyQpXCqaJUonJpUcFHKeZBT6ysUh6R7Z7Vulsr5vpCsiPyYvUYOIBbN2bi60UYA56tBOwQka1WMlaU8DxhRcqAQrUmM2ukrj-ZjL6HSuJpKPifZhF504vXBV3_n4vHl3_Gc3JzcHx4oA_2jvafkFsMpR9znfJtstnMFv4pwLjGPgu6Q8m3q1bW3zIgV8Y |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwELfGEIgXxDeBAUaCJ4ia-CN2HhACRrUxmJBgUt-M7ThbNdqUNhXqv8Zfx10-OpWPve0lUhOnuvjufL87n-8IeaYZF84xH2OhkFi4HFRKyxCHkquiAATgS3QUPx1me0fiw0iOtsiv_iwMplX2a2KzUBeVxxj5gClAvuDKCT4ou7SIz7vD17MfMXaQwp3Wvp1GKyIHYfUT3LfFq_1d4PVzxobvv77bi7sOA7GXIq1RRJgKLCsyD2bNOgbwXiTWMxe4zaVKgpelk3mQCfdBhrxIREh1UgYOuAGu8L-XyGXFAVWBLqmRWsd3sPK6FqI7p5NwPViIZlUCIwlazWUesw1b2LQM-BfO_Ttd848928YUDm-Q6x2GpW9aobtJtsL0FrnSdrVc3Sb-iy0DLebL4wXFMC_Fksh0VtWYmATv1RV1YEJP6cSCWz22tEZ7CfKGgTuKJaXAaBXUrailixmmesST8QQPW1JY4-AnEHWHHF3ITN8l29NqGu4TqryTRcKszzIlAL5agCiptiFnGMgJSUTSflaN7wqdY7-N76bZcOfatJwwwAnTcMKwiLxYvzNry3ycO_otMms9Ekt0Nzeq-bHpNN6kLMt1IbzOCy1Kn-YlfJRmAXTGyTLlEdnpWW26dWNhzqQ8Ik_Xj4EDuI1jp6FaNmPAy5WAIyJyr5WMNSVcJSxPGVCoN2Rmg9TNJ9PxSVNVPG2K_6dZRF724nVG1__n4sH5n_GEXAU1NR_3Dw8ekmsMhR_TntQO2a7ny_AIEF3tHjeqQ8m3i9bV33ZPXAU |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Safe+drugs+with+high+potential+to+block+malaria+transmission+revealed+by+a+spleen-mimetic+screening&rft.jtitle=Nature+communications&rft.au=Carucci%2C+Mario&rft.au=Duez%2C+Julien&rft.au=Tarning%2C+Joel&rft.au=Garc%C3%ADa-Barbaz%C3%A1n%2C+Irene&rft.date=2023-04-07&rft.issn=2041-1723&rft.eissn=2041-1723&rft.volume=14&rft.issue=1&rft.spage=1951&rft_id=info:doi/10.1038%2Fs41467-023-37359-2&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2041-1723&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2041-1723&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2041-1723&client=summon |